Rob Tyler dedicates his practice to helping entrepreneurs grow emerging technology companies in a variety of industries, including information technology, life sciences, medical devices, healthcare, nanotechnology and advanced materials.  He represents clients in a wide range of transactions including equity and debt financings, intellectual property and technology licensing, strategic alliances and partnerships, mergers and acquisitions and general corporate matters.  Moreover, he has an extensive network of contacts with potential investors and other resources of significant value to his clients.  Rob serves as Co-Chair of the firm's Emerging Technology practice.
        

Rob Tyler dedicates his practice to helping entrepreneurs grow emerging technology companies in a variety of industries, including information technology, life sciences, medical devices, healthcare, nanotechnology and advanced materials.  He represents clients in a wide range of transactions including equity and debt financings, intellectual property and technology licensing, strategic alliances and partnerships, mergers and acquisitions and general corporate matters.  Moreover, he has an extensive network of contacts with potential investors and other resources of significant value to his clients.  Rob serves as Co-Chair of the firm's Emerging Technology practice.

Rob has more than 25 years of experience in business and corporate law.  He is a member of the board of trustees for NC State's Kenan Institute for Engineering, Technology and Science.  In addition, he is a co-founder of The Medical Innovators Collaborative (MEDIC).  He served on the executive committee and the board of directors of the Council for Entrepreneurial Development (CED) and on the board of directors of NC IDEA.  He is a graduate of the University of Richmond, where he earned his J.D. and B.S, and he serves on the board of directors of the Richmond Law Advisory Board.  Previously, he was the president of the University of Richmond Law School Alumni Association.

                

  • Represented a power distribution and management technology company in its initial preferred stock financing
  • Represented an RFID technology company in multiple preferred stock financings
  • Represented a nanotechnology company in multiple preferred stock financings and development and supply agreements
  • Represented a pharmacogenetics company in a worldwide license to a global pharmaceutical company of a biomarker for the risk of Alzheimer's disease
  • Represented a vaccine company in multiple preferred stock and convertible promissory note financings
  • Represented a pharmacogenetics company in a strategic alliance with a global pharmaceutical company
  • Represented an advanced materials company in multiple preferred stock and convertible promissory note financings
  • Represented a microscopy company in multiple preferred stock financings
  • Represented an e-procurement information technology and services company in strategic business acquisitions
  • Represented a medical device company in national and international clinical study agreements
  • Represented a health care information technology company in its sale to a publicly-traded company
  • Represented a facilities management company in a software license to a Fortune 500 company
  • Represented an insurance agency in a software license and services agreement
  • Represented a regional venture capital firm in a preferred stock investment in a mobile application development and advertising sales company
  • Represented a software development company in a worldwide license to a global information technology company of a security technology for mobile devices
  • Represented a compliance and security solutions and services company in the sale of its assets